STOCK TITAN

Evaxion Biotech A/S - EVAX STOCK NEWS

Welcome to our dedicated news page for Evaxion Biotech A/S (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evaxion Biotech A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evaxion Biotech A/S's position in the market.

Rhea-AI Summary
Evaxion Biotech A/S (EVAX) will host a Research & Development Day on March 19, 2024, showcasing its AI-Immunology™ platform for vaccine development. The event will feature talks from scientists, highlighting the platform's predictive capabilities for addressing medical needs in cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
-
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) successfully completes initial phases of vaccine collaboration with MSD, a leading pharma company, showcasing the potential of AI-Immunology™ powered vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). The closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater for ten consecutive business days from January 22, 2024, to February 02, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
none
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) closed a public offering of 3,750,000 of its American Depositary Shares (ADSs) and warrants, raising $15 million. MSD Global Health Innovation Fund, a shareholder since December 2023, participated in the offering. The net proceeds will be used to advance the preclinical and clinical pipeline and for operating expenses and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
offering
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced the pricing of a public offering of 3,750,000 of its American Depositary Shares (ADSs) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS. MSD Global Health Innovation Fund, a shareholder since December 2023, is also participating in this offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.05%
Tags
offering
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is expanding its commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs). This AI-Immunology™ powered vaccine concept offers the potential to provide treatment solutions to cancer patients unresponsive to conventional cancer immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024, with a focus on delivering treatment solutions to previously unresponsive cancer patients. Evaxion's Chief Scientific Officer, Birgitte Rønø, expresses optimism about the significant potential of ERV-based vaccines and the company's commitment to improving healthcare through innovative and AI-powered approaches. The company also presented recent insights at the American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
113.43%
Tags
AI
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced a change in the ratio of its American Depositary Shares (ADSs) to its ordinary shares, with the new ratio of 1 ADS representing 10 ordinary shares. This change, effective from January 22, 2024, is intended to support liquidity and enable the company to regain compliance with the Nasdaq minimum bid price requirement. The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s equity. However, no assurance has been given regarding the proportionate increase in the ADS trading price after the change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.3%
Tags
none
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares from 1:1 to 1:10. This change is expected to become effective on Jan. 15, 2024. Evaxion is a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) closes private placement with gross proceeds of $5.3 million, including a 25% investment from MSD Global Health Innovation Fund. The private placement involved the sale of 9,726,898 ordinary shares represented by ADSs and accompanying warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announced its refined strategy with increased focus on value realization via partnerships based on the AI-Immunology™ platform. The company reported solid progress with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model. They also priced a bridge financing round expected to raise $5.3 million, aiming to fund operations until March 2024. The company aims to fund 2024 cash burn with income from business development activities, expecting cash burn at the level of $14 million in 2024. Evaxion's CEO highlighted the refined strategy's focus on value realization and reduced cash burn, emphasizing strong business execution based on the new strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
earnings
Evaxion Biotech A/S

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

16.31M
34.54M
17.99%
1.01%
0.4%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Denmark
Horsholm

About EVAX

since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai